The accreditors of this session require that you periodically check in to verify that you are still attentive. Please click the button below to indicate that you are.
Credits: None available.
Live Program Date: Wednesday, September 15, 2021
Program Number: 21EL-674
Educational Track: Technical/Clinical
Topics: Apheresis, Cellular Therapy, Collection, Complications, Inventory, Management Operations, Outcomes, Outcomes/Engagement, Patient Blood Management, Patient Transfusion, Special Patients and Situations, Therapeutic Apheresis, Therapeutic Goals, Transfusion Process, Transfusion Safety
Intended Audience: Directors, Hospital Blood Banks, Hospitals, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
Teaching Level: Advanced, Intermediate
(titles and affiliations at the time of the live program)
Director/Moderator: Huy P. Pham, MD, MPH, Medical Director, National Marrow Donor Program (NMDP), Seattle, WA
Speakers: Patricia A. Shi, MD, Medical Director, New York Blood Center, New York, NY
Ross Fasano, MD, Associate Professor, Emory University, Atlanta, GA
Monika Paroder, MD, PhD, Assistant Professor, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
Sickle cell disease is affected approximately 100,000 people in the United States. It is a major public health concern and the patients have a significant morbidity and mortality. At this time, transfusion of red blood cells (RBCs) is one of the main treatment strategies for this disease. However, transfusion is potentially associated with multiple complications, including transfusion-transmitted infections and alloimmunizations.
Given that there are few quality studies investigated the effect of simple vs. exchange transfusion in patients with sickle cell disease, this program will summarize the current data and expert opinion on the use of each treatment modality. Key considerations that physicians should be aware of when choosing between treatment options as well as challenges in pediatric patients will also be addressed. Lastly, novel therapies in the treatment of sickle cell disease, including cellular therapies, will be discussed.
After participating in this educational activity, participants should be able to:
How to Claim Continuing Education Credit
You must be logged in and own this session in order to post comments.
How to Claim CE Credit